Loading
A phase 1/2 trial in pancreatic cancer, run by University Hospital Tuebingen, not yet recruiting.
CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa) is a phase 1/2, interventional study registered as NCT07153289 by University Hospital Tuebingen, with a registry enrolment figure of 38 participants, started 2026-07 and due to reach its primary completion in 2028-12. Interventions recorded: CD318-CAR-T cells. Conditions listed: Carcinoma, Pancreatic Ductal; Pancreatic Neoplasms. Primary outcome: Incidence and severity of dose-limiting toxicities (DLTs) and adverse events (AEs) after CD318-CAR-T cell infusion.. No results are recorded here; the registry entry is the source.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.